Medicenna Therapeutics【MDNA】銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

1.79

買値

1.70

売値

1.83

出来高

49,021

1.68 日の範囲 1.80

0.38 52 週間の範囲 2.98

時価総額

124.65M

前日終値

1.72

始値

1.72

時刻

100

1.79

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

81,900

発行済株式数

69,637,000

配当利回り

PER

-4.84

1 株当たり利益 (EPS)

-0.37

歳入

純利益

-25.47M

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.medicenna.com

本社

Toronto, Ontario, Can

設立

Medicenna Therapeutics Corp is listed in the Biological Pds,ex Diagnstics sector of the トロント証券取引所 with ticker MDNA. The last closing price for Medicenna Therapeutics was $1.72. Over the last year, Medicenna Therapeutics shares have traded in a share price range of $ 0.38 to $ 2.98.

Medicenna Therapeutics currently has 69,637,000 shares in issue. The market capitalisation of Medicenna Therapeutics is $119.78 million. Medicenna Therapeutics has a price to earnings ratio (PE ratio) of -4.84.

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive...

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and...

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells...

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression...

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor...

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna...

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.14	-7.25388601036	1.93	1.93	1.68	38929	1.77804375	CS
4	0.18	11.1801242236	1.61	2.14	1.41	61724	1.78138326	CS
12	-0.21	-10.5	2	2.62	1.27	81900	1.98608945	CS
26	-0.29	-13.9423076923	2.08	2.62	1.27	77782	2.0265654	CS
52	1.34	297.777777778	0.45	2.98	0.38	99678	1.82705182	CS
156	-0.37	-17.1296296296	2.16	2.98	0.215	62823	1.43122805	CS
260	0.03	1.70454545455	1.76	7.25	0.215	73945	2.77555662	CS

銘柄コード	株価	出来高
VRTSVertiqal Studios Corporation	$ 0.015 (50.00%)	546k
FLNTFlint Corporation	$ 0.03 (50.00%)	153k
TSNDTerrAscend Corp	$ 0.97 (18.29%)	403.49k
FLOWFlow Beverage Corp	$ 0.165 (13.79%)	257.07k
ARAAclara Resources Inc	$ 0.53 (12.77%)	125.26k
AKT.BAkita Drilling Ltd	$ 2.03 (-55.48%)	127
RTGRTG Mining Inc	$ 0.025 (-37.50%)	10.35k
WRXWestern Resources Corp	$ 0.035 (-36.36%)	1.09M
CNTCentury Global Commodities Corporation	$ 0.025 (-16.67%)	80k
DIAMStar Diamond Corporation	$ 0.025 (-16.67%)	466.1k
CNQCanadian Natural Resources Ltd	$ 43.84 (-0.25%)	20.11M
BCEBCE Inc	$ 33.78 (-0.79%)	10.73M
ACAir Canada	$ 22.60 (-9.31%)	8.39M
CVECenovus Energy Inc	$ 21.13 (-0.33%)	7.45M
SUSuncor Energy Inc	$ 51.33 (-0.62%)	7.41M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Medicenna Therapeutics Corp (MDNA)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Medicenna Therapeutics Corp について

MDNA 最新ニュース

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Medicenna Therapeutics Corp (MDNA) 銘柄情報

Medicenna Therapeutics Corp (MDNA)

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Medicenna Therapeutics Corp について

MDNA 最新ニュース

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手